Evidence map›Paper›PMID 42703616›Full record

Trial reportOpen forum infectious diseases2026

Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.

Antonella Castagna, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Andrew Clark, Cynthia Donovan, Bryn Jones, Manyu Prakash

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonella CastagnaInfectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy.
Iacopo MarconViiV Healthcare, Verona, Italy.
Fangfang DuGSK, Collegeville, Pennsylvania, USA.
Bo LiGSK, Collegeville, Pennsylvania, USA.
Marcia WangGSK, Collegeville, Pennsylvania, USA.
Andrew ClarkViiV Healthcare, London, UK.ORCID https://orcid.org/0000-0002-5213-9624
Cynthia DonovanViiV Healthcare, Durham, North Carolina, USA.
Bryn JonesViiV Healthcare, London, UK.ORCID https://orcid.org/0000-0001-9296-367X
Manyu PrakashViiV Healthcare, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Constructing suppressive regimens for individuals with multidrug-resistant HIV-1 can be challenging. Separate analyses of 96-week outcomes from the phase 3 VIKING-3 and BRIGHTE studies demonstrate that twice-daily dolutegravir-based and fostemsavir-based regimens each provide robust viral suppression, favorable safety profiles, and CD4+ T-cell count improvement in this population.

Indexed as

dolutegravirefficacyfostemsavirHIV-1multidrug resistance

Identifiers

PMID42703616
PMCPMC13546792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.